Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

Jean-Marc Ferrero; Anne-Claire Hardy-Bessard; Olivier Capitain; Alain Lortholary; Bruno Salles; Philippe Follana; Robert Herve; Mathilde Deblock; Jérôme Dauba; Mustapha Atlassi; Rémy Largillier

doi:10.1002/cncr.30170

Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study

Cancer ◽

10.1002/cncr.30170 ◽

2016 ◽

Vol 122 (20) ◽

pp. 3119-3126 ◽

Cited By ~ 8

Author(s):

Jean-Marc Ferrero ◽

Anne-Claire Hardy-Bessard ◽

Olivier Capitain ◽

Alain Lortholary ◽

Bruno Salles ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Faculty Opinions recommendation of Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.734230835.793559070 ◽

2019 ◽

Author(s):

Ahmad Awada

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Preliminary Data ◽

Triple Negative ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Abstract P5-11-14: Palbociclib in combination with anastrozole or exemestane as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study

10.1158/1538-7445.sabcs19-p5-11-14 ◽

2020 ◽

Author(s):

Manfred Welslau ◽

Norbert Marschner ◽

Ulrike Söling ◽

Cosima Brucker ◽

Oliver J. Stoetzer ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

First Line Therapy ◽

Her2 Breast Cancer ◽

Line Therapy ◽

Phase 2 Study

Download Full-text

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-014-2923-9 ◽

2014 ◽

Vol 146 (2) ◽

pp. 321-328 ◽

Cited By ~ 32

Author(s):

Kristi McIntyre ◽

Joyce O’Shaughnessy ◽

Lee Schwartzberg ◽

Stefan Glück ◽

Erhan Berrak ◽

...

Keyword(s):

Breast Cancer ◽

Growth Factor Receptor ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Epidermal Growth ◽

Locally Recurrent

Download Full-text

Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)

10.1158/1538-7445.sabcs20-ps12-28 ◽

2021 ◽

Author(s):

Peter Schmid ◽

Peter Savas ◽

Enrique Espinosa ◽

Valentina Boni ◽

Antoine Italiano ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Locally Advanced ◽

First Line ◽

First Line Therapy ◽

Line Therapy ◽

Phase 1B

Download Full-text

Abstract CT139: First-line therapy with dacomitinib, an orally available pan-her tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: Results of an open label, single-arm, single-center, phase 2 study

10.1158/1538-7445.am2017-ct139 ◽

2017 ◽

Author(s):

Andrea Necchi ◽

Salvatore Lo Vullo ◽

Daniele Raggi ◽

Patrizia Giannatempo ◽

Nicola Nicolai ◽

...

Keyword(s):

Kinase Inhibitor ◽

Locally Advanced ◽

Phase 2 ◽

Single Center ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Penile Squamous Cell Carcinoma

Download Full-text

First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study

BJU International ◽

10.1111/bju.14013 ◽

2017 ◽

Vol 121 (3) ◽

pp. 348-356 ◽

Cited By ~ 30

Author(s):

Andrea Necchi ◽

Salvatore Lo Vullo ◽

Federica Perrone ◽

Daniele Raggi ◽

Patrizia Giannatempo ◽

...

Keyword(s):

Kinase Inhibitor ◽

Locally Advanced ◽

Phase 2 ◽

First Line ◽

Single Centre ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Phase 2 Study ◽

Penile Squamous Cell Carcinoma

Download Full-text

1859 Clinical effects of prior chemotherapy on eribulin: Update and subgroup analysis of phase 2 multicenter single arm study of eribulin mesylate as first-line therapy for HER2 negative locally advanced or metastatic breast cancer

European Journal of Cancer ◽

10.1016/s0959-8049(16)30809-7 ◽

2015 ◽

Vol 51 ◽

pp. S285

Author(s):

S. Nishimura ◽

T. Takashima ◽

H. Kawajiri ◽

S. Kashiwagi ◽

S. Noda ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Clinical Effects ◽

Phase 2 ◽

First Line ◽

Eribulin Mesylate ◽

Prior Chemotherapy ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Abstract P3-13-07: A-TaXel: Multicenter phase II combination of bevacizumab (A) with weekly paclitaxel (Ta) and capecitabine (Xel) in first line treatment for patients with triple negative metastatic or locally advanced breast cancer (TNMBC), a GINECO study

10.1158/0008-5472.sabcs13-p3-13-07 ◽

2013 ◽

Author(s):

J-M Ferrero ◽

A-C Hardy-Bessard ◽

O Capitain ◽

A Lortholary ◽

B Salles ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Multicenter Phase ◽

First Line Treatment

Download Full-text

Abstract P4-22-08: A single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer

10.1158/1538-7445.sabcs16-p4-22-08 ◽

2017 ◽

Cited By ~ 2

Author(s):

I Krop ◽

J Cortes ◽

K Miller ◽

MT Huizing ◽

L Provencher ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Advanced Breast ◽

Clinical Activity ◽

Phase 2 ◽

Efficacy And Safety ◽

Phase 2 Study

Download Full-text

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30450-3 ◽

2017 ◽

Vol 18 (10) ◽

pp. 1360-1372 ◽

Cited By ~ 147

Author(s):

Sung-Bae Kim ◽

Rebecca Dent ◽

Seock-Ah Im ◽

Marc Espié ◽

Sibel Blau ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase 2 ◽

First Line ◽

Double Blind ◽

Double Blind Placebo ◽

First Line Therapy ◽

Phase 2 Trial ◽

Line Therapy

Download Full-text